Compare EAT & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EAT | BLTE |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.2B |
| IPO Year | 1994 | 2021 |
| Metric | EAT | BLTE |
|---|---|---|
| Price | $140.56 | $142.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 7 |
| Target Price | $183.00 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.3M | 109.8K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 144.71 | N/A |
| EPS | ★ 7.90 | N/A |
| Revenue | ★ $5,384,200,000.00 | N/A |
| Revenue This Year | $9.00 | N/A |
| Revenue Next Year | $5.49 | $492.11 |
| P/E Ratio | $17.65 | ★ N/A |
| Revenue Growth | ★ 21.95 | N/A |
| 52 Week Low | $100.30 | $56.68 |
| 52 Week High | $187.12 | $200.00 |
| Indicator | EAT | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 39.20 |
| Support Level | $131.79 | $103.94 |
| Resistance Level | $154.23 | $172.02 |
| Average True Range (ATR) | 6.54 | 7.26 |
| MACD | 0.67 | -0.56 |
| Stochastic Oscillator | 65.62 | 34.58 |
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.